Navigation Links
IPC The Hospitalist Company Reports Record First Quarter 2009 Results
Date:5/4/2009

to recruit new physicians to add to our existing practices. In the first quarter, we also completed two in-market acquisitions in Phoenix, which strengthened our foothold in one of our largest markets. Our acquisition pipeline remains robust in this highly fragmented industry, and we continue to evaluate opportunities across the hospitalist sector. We remain confident that we can continue to grow and penetrate current and new markets through this combination of organic growth and acquisitions. With less than 5% of our encounters coming from elective in-patient stays and uninsured patients remaining stable at approximately 7% of our encounters, we believe we are very well positioned in this challenging economic environment."

First Quarter 2009

IPC's first quarter 2009 patient encounters rose 18% to 810,000, compared to 684,000 in the same period last year. Net revenue for the first quarter was $76.1 million, an increase of $15.5 million, or 25.6%, from $60.6 million for the prior year quarter. Of this $15.5 million increase, $11.8 million, or 76.1%, was attributable to same-market area growth and $3.7 million was attributable to revenue generated from a new market acquisition, which was completed in the third quarter of 2008. The change in same-market area net revenue was the result of an 11.9% increase in patient encounters, a 5.9% increase in patient revenue per encounter and an increase in hospital contract revenue. The increase in patient revenue per encounter was partially due to an increase in Medicare reimbursement rates for the billing codes applicable to the services performed by the Company's hospitalists, as well as improvements in billing processes and collections.

Physician practice salaries, benefits and other expenses for the three months ended March 31, 2009 were $55.5 million, or 72.9%, of net revenue compared to $43.9 million, or 72.6%, of net revenue for the three months ended March 31, 2008. Ph
'/>"/>

SOURCE IPC The Hospitalist Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results
2. IPC The Hospitalist Company Presents IPC Hospitalist of the Year Award to Tim Osonma, M.D.
3. IPC The Hospitalist Company Acquires Arizona Practice
4. Spokane Hospitals Engage Sound Inpatient Physicians(TM) as Hospitalists in Spokane
5. IPC The Hospitalist Company Adopts E-Proxy to Reduce Environmental Impact
6. IPC The Hospitalist Company Reports Record Fourth Quarter and Full Year 2008 Results
7. IPC The Hospitalist Company Receives Best IPO Award from Los Angeles Venture Association
8. IPC The Hospitalist Company Acquires Missouri Practice Group
9. IPC The Hospitalist Company, Inc. to Present at 27th Annual J.P. Morgan Healthcare Conference
10. Physician Staffing Trends and Hospitalist Jobs Fuel Growth at Locum Leaders
11. IPC The Hospitalist Company Acquires Two Florida Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... 20, 2014 The newly updated Worldwide ... of thousands of facts, figures and forecasts on the ... medical sector forecast categories the Worldwide Medical Market ... and national views on the worldwide medical market to ... report gives you data for 2010-2019, covering each country ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
(Date:10/20/2014)... 2014 T.E.N., a technology and ... today that William H. Murray, renowned author and ... Luminary Leadership Award winner. Presented annually, the ISE® ... outstanding leader and industry practitioner for his or ... the information security industry. , Formerly with IBM, ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... Marshall Erdman &,Associates (Erdman) was rated ... 2008 Construction & Design Survey. The survey,compares ... it,examines year-over-year sales, contracted square footage fluctuations, ... number of architects, engineers,and interior designers., ...
... important international relationships is top of the agenda ... Dr Raisa Monteiro, when she meets with leading ... One of two Australian life scientists chosen from ... prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro ...
... HILL, N.C., March 27 Successful alliances that,lead ... each partner,company are contingent on the selection of ... efforts orient themselves towards,alliance by first articulating the ... using particular selective criteria., Best Practices, LLC,s ...
... Leading Developer of Practice Information Management Software Introduces Comprehensive Patient ... ... Back-Up, DALLAS, March 27 Eklin ... and,Communications System) and Practice Management software for veterinary care,(VIA(R)), is showcasing ...
... Lead Product Candidate, INTERLEUKIN-7, currently in ... cancer, PRINCETON, N.J. and PARIS, March 27 ... protein,production company, announced today that it has entered ... a clinical stage,biopharmaceutical company focused on research and ...
... LLC,( http://www.homeguardian.us/ ) has announced the release of ... status of seniors in their,homes while enabling professional ... the detection of falls, which constitute the largest,cause ... the United States., The systems were developed ...
Cached Medicine News:Health News:'Modern Healthcare' Names Marshall Erdman Nation's Top Design-Build Company 2Health News:DendriMed scientist seeks to fast-track success 2Health News:Eklin VIA(R) Showcases Hospitalization Functionality to Veterinary Care Market 2Health News:Eklin VIA(R) Showcases Hospitalization Functionality to Veterinary Care Market 3Health News:Laureate Announces Second Manufacturing Agreement with Cytheris 2Health News:Laureate Announces Second Manufacturing Agreement with Cytheris 3Health News:Home Guardian Releases Innovative Sensor System to Keep Seniors Safe 2
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... RiOs systems produce Type III, laboratory-grade pure ... are fed directly with potable tap water ... compact system design that is easy to ... the water produced at a low operating ...
... 10,400 more samples than traditionally-insulated freezers, ... panel technology maximizes storage capacity. Freezer ... compartments; two adjustable-height shelves included. Patented ... energy consumption and extends compressor life. ...
... The NU-5510 DHD AutoFlow Direct ... HEPA filtration guarantying the greatest control ... cycles, both at 95C wet decontamination ... are exceptionally useful for cell line ...
... Simple, economical, moderate-sized CO2 incubator with ... with glass inner door, HEPA filtered ... minimize sample exposure. Simple, large character ... IR CO2 sensing and mulitple temperature ...
Medicine Products: